Glaukos.
public company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
One to three months ago
-
Glaukos Corporation increased its holdings in its own stock.Some support1 report
-
Glaukos filed reports with the SEC regarding its stock holdings on August 6, 2026.Some support1 report
-
Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.Well supported6 reports
-
Glaukos CFO Alex R. Thurman sold shares of the company's stock.Some support1 report
-
Analyst firm assumed coverage on Glaukos shares.Some support1 report
-
Citigroup raised its price target and gave a buy rating for Glaukos, while Leana Wen sold Glaukos stock.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Glaukos this week
News at the entities that move Glaukos most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Glaukos
-
Citigroup TransactionalCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Glaukos
-
Royal Bank of Canada TransactionalRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves Glaukos
-
Abbott Laboratories OperationalMarketBeat listed Abbott, Eli Lilly, Pfizer, Gilead, AbbVie, and McKesson as stocks to watch on June 7, 2026.Moves Glaukos
-
Needham & Company Mentioned togetherSEC is overseeing public offering filings involving Broadridge Financial Solutions.Moves Glaukos
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Glaukos
Connections
The 11 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Tom Burns Structural
Tom Burns holds the formal leadership roles of Chairman and CEO of Glaukos.
-
Thomas Burns Structural
Thomas Burns serves as the Chairman and CEO of Glaukos.
-
FDA Structural
Glaukos's ability to market its products is dependent on receiving formal approval from the FDA.
-
Chris Lewis Structural
Chris Lewis serves as VP of Investor Relations for Glaukos.
-
SEC Structural
Glaukos is subject to regulatory oversight by the SEC regarding its stock holdings and required filings.
-
Royal Bank of Canada Transactional
Royal Bank of Canada has increased its holdings in Glaukos Corporation stock.
-
Needham & Company Mentioned together
Needham & Company provides analyst coverage on Glaukos shares.
-
Aliso Viejo Shared context
The company is located in Aliso Viejo, California.
Show all 11 connections
-
Citigroup Transactional
Citigroup assessed Glaukos by raising its price target and assigning a buy rating.
-
Abbott Laboratories Operational
Both Abbott Laboratories and Glaukos actively compete within the medical device stock market.
-
Leana Wen Transactional
Leana Wen sold shares of Glaukos stock.
History
Events by the month they beganAugust 2026
2 eventsJuly 2026
3 eventsJune 2026
3 events- Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.
- Thomas Burns was appointed CEO and chairman of Glaukos, noting that EU certification is key to maintaining the company's presence in Europe.
- Glaukos shares underperformed the S&P 500 on July 31, 2025.